Loading...
•
Jun 30, 2023
Mink Therapeutics Q2 2023 Earnings Report
Reported second quarter 2023 results and provided a corporate update.
Key Takeaways
MiNK Therapeutics reported its second quarter 2023 results, highlighting clinical progress with agenT-797 and the planned launch of a randomized Phase 2 trial in 2L gastric cancer. The company ended the quarter with a cash balance of $10.6 million.
Made significant clinical progress with agenT-797, showing persistence and clinical benefit in patients with solid tumor cancers.
Announced the planned launch of a randomized Phase 2 trial in 2L gastric cancer, expected to be fully externally funded and launch in early 3Q2023.
Preclinical data showed MiNK-215 exhibits robust therapeutic activity in non-small cell lung cancer models.
Data demonstrated the tolerable safety profile and survival benefit of iNKT cells in respiratory distress.
Mink Therapeutics
Mink Therapeutics
Forward Guidance
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797, MiNK-215, and iNKT cells, mechanism of action, potency and safety, interim or top-line data, including statements regarding preclinical data of MiNK-215, the anticipated benefits of agenT-797 and MiNK-215, and clinical development plans and timelines.